Canterbury DHB


CMV Prevention

CMV infection can cause serious problems particularly in allografted patients where either the donor or recipient or both are CMV seropositive indicating previous exposure. Our CMV disease control strategy includes preventing primary infection from blood products in previously uninfected patients, identifying and treating incipient CMV disease and in patients at high risk of disease, administering prophylactic treatment.

For a definitive discussion of the management of CMV infection in HSCT see Emery, V., M. Zuckerman, et al. (2013). "Management of cytomegalovirus infection in haemopoietic stem cell transplantation." Br J Haematol 162(1): 25-39.


Potential recipients of haemopoietic stem cell transplants

In This Section

CMV Monitoring

Allografts (Standard or RIC)

Allografts (Standard or RIC) at LOW Risk for CMV viraemia

Other intensively treated patients

CMV Monitoring

Note: Canterbury Health Laboratories reports CMV viral load in International Units/mL (iu/mL). The local conversion for the current Abbott assay is: IU/mL x 0.64 = copies/mL. Therefore a threshold of 1000 copies/mL is equivalent to approximately 1500 iu/mL. See section on CMV Infection - Treatment for a discussion of triggers for starting treatment.

Allografts (Standard or RIC)

Primary prophylaxis with ganciclovir is not generally recommended, as toxicity outweighs efficacy.

Allografts (Standard or RIC) at LOW Risk for CMV viraemia

When both the patient and donor are CMV seronegative, all patients receiving allografts are at Low Risk.

Other intensively treated patients

About this Canterbury DHB document (9322):

Document Owner:

Andrew Butler (see Who's Who)

Last Reviewed:

May 2021

Next Review:

May 2023


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 9322